Max Lab > Lab Test in Hisar > Lab Test in Sector 13 > MRD-ALL Panel
₹ 12500
10% OFF for Senior Citizens | USE CODE SS10 *
@3x.png)
Description
Minimal residual disease is defined as the small number of cancer cells that remain in the body after cancer treatment. Measurable or minimal residual disease (MRD) testing is used to observe whether the cancer treatment is working fine or not. It also helps to plan further treatment plans. MRD test in Sector 13, Hisaring is mainly used in blood cancers, such as leukaemia, lymphoma, and myeloma. MRD test in Sector 13, Hisar for acute leukaemia is the strongest independent prognostic predictor. Also, for the treatment of adult and paediatric acute lymphocytic leukaemia (ALL), MRD test in Sector 13, Hisaring is a part of routine test in Sector 13, Hisaring. Additionally, in relapsed settings of multiple myeloma, MRD test in Sector 13, Hisaring is a predictor of survival outcomes. The standard procedure of the MRD test in Sector 13, Hisar is to assess the number of myeloma cells in a bone marrow sample using techniques like genetic sequence analysis, next-generation sequencing and flow cytometry: next-generation flow.
MRD test in Sector 13, Hisar is done to find any remaining cancer cells that may be left in small numbers. MRD lab test in Sector 13, Hisars use sensitive methods which can find even a single cancer cell in 1 million healthy cells. MRD blood test in Sector 13, Hisars include methods such as polymerase chain reaction (PCR), multiparametric flow cytometry, and next-generation sequencing (NGS). Such test in Sector 13, Hisars are used after initial treatments for blood cancers like multiple myeloma. It helps to observe how well a person’s body is responding to treatment, if the person is in full remission, and to check if remission is stable or not or if there is any recurrence.
MRD test in Sector 13, Hisar results can affect a person’s treatment by helping in making treatment decisions and improving patient outcomes as it helps in:
Description
Minimal residual disease is defined as the small number of cancer cells that remain in the body after cancer treatment. Measurable or minimal residual disease (MRD) testing is used to observe whether the cancer treatment is working fine or not. It also helps to plan further treatment plans. MRD test in Sector 13, Hisaring is mainly used in blood cancers, such as leukaemia, lymphoma, and myeloma. MRD test in Sector 13, Hisar for acute leukaemia is the strongest independent prognostic predictor. Also, for the treatment of adult and paediatric acute lymphocytic leukaemia (ALL), MRD test in Sector 13, Hisaring is a part of routine test in Sector 13, Hisaring. Additionally, in relapsed settings of multiple myeloma, MRD test in Sector 13, Hisaring is a predictor of survival outcomes. The standard procedure of the MRD test in Sector 13, Hisar is to assess the number of myeloma cells in a bone marrow sample using techniques like genetic sequence analysis, next-generation sequencing and flow cytometry: next-generation flow.
MRD test in Sector 13, Hisar is done to find any remaining cancer cells that may be left in small numbers. MRD lab test in Sector 13, Hisars use sensitive methods which can find even a single cancer cell in 1 million healthy cells. MRD blood test in Sector 13, Hisars include methods such as polymerase chain reaction (PCR), multiparametric flow cytometry, and next-generation sequencing (NGS). Such test in Sector 13, Hisars are used after initial treatments for blood cancers like multiple myeloma. It helps to observe how well a person’s body is responding to treatment, if the person is in full remission, and to check if remission is stable or not or if there is any recurrence.
MRD test in Sector 13, Hisar results can affect a person’s treatment by helping in making treatment decisions and improving patient outcomes as it helps in:
.png)
7982100200
Test Name 
Sample Type 
Gender 
Age group 
This Test Includes 
Price
To reach our help desk call 9213188888